Canadian Court Grants Allergan’s Request to Prohibit Generic Eye Drop

The Federal Court of Canada has granted Allergan Inc. prohibition orders against production by two generic pharmaceutical manufacturers of generic versions Lumigan RC eye drops to treat glaucoma and ocular hypertension (Allergan, Inc. v. Cobalt Pharmaceuticals, Inc.; Allergan, Inc. v. Apotex, Inc.).

The orders block Cobalt Pharmaceuticals Inc. and Apotex Inc. from producing generic versions of the drug, a combination of 0.03 percent bimatoprost and 50 parts per million benzalkonium chloride, until its patent expires in 2026, Justice James W. O’Reilly said in the June 13 rulings, made public June 25.

The largely identical rulings, which awarded ...